EPIGRAL Epigral Q2 FY26 results (Jul–Sep 2025) and concall
Epigral reported a challenging Q2 FY26 with revenue declining 4% QoQ to ₹589 crores and EBITDA dropping 19% QoQ to ₹132 crores, primarily due to lower realizations in products like CPVC and hydrogen peroxide, and subdued plant utilization. Despite H1 headwinds, the company maintains a healthy EBITDA margin of 25% and significantly improved its net debt to EBITDA ratio to 0.8x. Management expects a stronger H2 FY26 with anticipated volume growth, improved utilization, and upcoming revenue contributions from new projects like Chlorotoluene, while also progressing on future CAPEX plans for divers
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 6.2%, net profit down 37.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 626 | 645 | 628 | 607 | 587 −6% |
| EBITDA | 178 | 183 | 173 | 163 | 132 −26% |
| Net profit | 81 | 104 | 87 | 161 | 51 −37% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
